PACE4 in Thyroid Cancer

NCT ID: NCT03160482

Last Updated: 2018-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

39 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-15

Study Completion Date

2018-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigation of thyroid nodules is limited by the fact that up to 49% of the fine needle aspirations (FNA) performed are of "indeterminate cytological signification". Moreover, no fully reliable molecular marker for thyroid cancer have been described. The goal of this project is to study the expression of a specific kind of protein convertase in benign and in malignant thyroid nodules to determine its potential as a biomarker.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients that underwent thyroidectomy at the CIUSSS de l'Estrie-CHUS will be recruited and classified according to the pathological diagnosis. An immunohistochemistry technique, developed and calibrated for the specific protein convertase studied, will be undertaken. Results will be interpreted by a specialized pathologist.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Nodule

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Papillary carcinoma, classical variant

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Follicular carcinoma

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Colloid nodule

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Hyperplastic nodule

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Adenomatoid nodule

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Follicular adenoma

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Papillary carcinoma, follicular variant

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Medullary carcinoma

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Lymphocytic thyroiditis

Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunohistochemistry

Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men of women, aged 18-100 y.-o.
* History of subtotal or total thyroidectomy at the "Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke" (CIUSSS de l'Estrie - CHUS) between January 2010 and May 2016.

Exclusion Criteria

* Refusal to participate to the study.
* Unavailability of the formalin-fixed, paraffin-embedded tissues.
* Uncertain pathological diagnosis.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Robert Day

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robert Day

PhD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Day, PhD

Role: PRINCIPAL_INVESTIGATOR

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CIUSSS de l'Estrie - CHUS

Sherbrooke, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Fradet L, Temmar R, Couture F, Belzile M, Fortier PH, Day R. Evaluation of PACE4 isoforms as biomarkers in thyroid cancer. J Otolaryngol Head Neck Surg. 2018 Oct 19;47(1):63. doi: 10.1186/s40463-018-0311-x.

Reference Type DERIVED
PMID: 30340539 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-1620

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.